• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Trazodone Probably Not Effective for Dementia
RESEARCH UPDATE

Trazodone Probably Not Effective for Dementia

October 1, 2022
Susan L. Siegfreid, MD
From The Carlat Geriatric Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Susan L. Siegfreid, MD. Dr. Siegfreid, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Sommerlad A et al, Int J Geriatr Psychiatry 2021;37(1):10

STUDY TYPE: Retrospective cohort study

Trazodone is often used to address insomnia and agitation in patients with dementia. Small randomized controlled trials have not found trazodone to be helpful in improving cognition or reducing the incidence of dementia. Nonetheless, recent mouse model studies have suggested trazodone might reverse aggregation of pathologic proteins found in dementia. Could this be a mechanism to protect against neurodegeneration? And could trazodone have a similar disease-modifying effect in ­humans?

To test out this theory, researchers conducted an observational cohort study using three UK mental health service registers. This was a retrospective study in which records of patients with dementia were reviewed to see if trazodone use correlated with improved dementia outcomes, as measured by Folstein Mini Mental Status Exam (MMSE) scores. 

The study period varied by site between 2006 and 2016. Individuals were included if they had dementia and were prescribed one of three antidepressants (trazodone, citalopram, or mirtazapine) for at least six weeks. All 2,199 study participants (average age of 79.3 + 3.0 years old; 65.3% female) had ICD-10 diagnostic codes for dementia. The predominant dementia subtype (78.8%) was neurodegenerative, non-vascular dementia. Average baseline MMSE score was 18.8 + 2.6. The average daily dose of trazodone was 101.8 mg/day (range 50–300 mg/day). 

Participants were followed until the last date of study medication use, date of death, or predetermined end of the study period. Participants taking both trazodone and either citalopram or mirtazapine were included in the trazodone group. When trazodone was switched to either citalopram or mirtazapine during the study, only data during trazodone use were analyzed. Individuals taking both mirtazapine and citalopram were excluded from the study, although the authors did not explain their rationale for this decision. 

The primary outcome was a change in MMSE scores over time. Disappointingly, no statistically significant cognitive benefit could be attributed to trazodone compared to citalopram or mirtazapine. After adjustment for dementia subtype, dementia severity at baseline, and severity of neuropsychiatric symptoms, these results remained nonsignificant. 

This was an observational, unblinded, nonrandomized study with baseline clinical differences between groups (including a much smaller trazodone group with significantly lower MMSE scores). As the researchers used a secondary mental health care database, we also don’t know about medication indications, concurrent medications, comorbid medical/psychiatric conditions, or the participants’ level of functioning. 

Carlat Take 

This large observational study revealed no signal that trazodone might protect against neurodegeneration. However, the study had a number of severe limitations, including opaque methodology and unequal groups at baseline, which may have influenced the results. The only way to know for sure whether trazodone is ineffective for dementia is to do a controlled clinical trial, but it’s unlikely that such a study will be conducted given these unpromising findings. However, trazodone remains useful as an off-label, adjunctive treatment for behavioral and psychological symptoms of dementia, and it remains a relatively safe medication to help with sleep.

Research Update
KEYWORDS cognition dementia geriatric psychiatry mmse neurodegeneration trazodone
    Susan L. Siegfreid, MD

    Dose-Dependent Mortality Risk for Second-Generation Antipsychotics in Young Adults

    More from this author
    www.thecarlatreport.com
    Issue Date: October 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives: Depression in Older Adults, CGPR, October/November 2022
    Assessing Suicide Risk in the Older Adult
    How to Identify and Treat Apathy and Late-Life Depression
    Complementary and Alternative Therapies for Late Life Depression
    Do White Matter Hyperintensities Predict Memory Loss with Electroconvulsive Therapy?
    Trazodone Probably Not Effective for Dementia
    Can Pimavanserin Treat Psychosis in Patients With Dementia?
    Less Sleep Correlated with Dementia
    CME Post-Test, Depression, CGPR, Oct/Nov/Dec 2022
    DOWNLOAD NOW
    Featured Book
    • HospPsychiatry_Spiral_Binding_Sm.png

      Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

      This comprehensive guide is designed to be a valuable resource for professionals working in...
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.